Despite the apparent insights into stroke pathophysiology, an abundance of promising targets in preclinical development, several underpowered phase I/II clinical trials that have detected signals of effectiveness, [15][16][17] and all large phase II/ III randomized controlled clinical trials of neuroprotectants
No takes yet. Share an insight, caveat, or question.
Dirnagl et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: